<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225273</url>
  </required_header>
  <id_info>
    <org_study_id>43USSA1705ext</org_study_id>
    <nct_id>NCT04225273</nct_id>
  </id_info>
  <brief_title>Extension Study for 43USSA1705</brief_title>
  <official_title>Open Label Extension Study for 43USSA1705 (A Randomized, Evaluator-blinded, Multi-center Study to Evaluate the Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety of Sculptra Aesthetic as a single regimen for correction of
      Nasolabial Fold (NLF) contour deficiencies after changes in reconstitution and injection
      procedures compared to the approved label.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events collected throughout the study period</measure>
    <time_frame>Baseline (initial treatment in pivotal study 43USSA1705) to Week 92</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of adverse events collected throughout the study period</measure>
    <time_frame>Baseline (initial treatment in pivotal study 43USSA1705) to Week 92</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to onset of adverse events collected throughout the study period</measure>
    <time_frame>Baseline (initial treatment in pivotal study 43USSA1705) to Week 92</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of adverse events collected throughout the study period</measure>
    <time_frame>Baseline (initial treatment in pivotal study 43USSA1705) to Week 92</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline on both sides of the face as assessed by the Evaluator using the Wrinkle Assessment Scale (WAS)</measure>
    <time_frame>Weeks 72 and 96 after Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate using the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Weeks 72 and 96 after Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FACE-Q Appraisal of Lines: Nasolabial Folds Questionnaire</measure>
    <time_frame>Weeks 72 and 96 after Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject satisfaction score using a 5-point subject satisfaction questionnaire</measure>
    <time_frame>Weeks 72 and 96 after Baseline</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Investigational Arm in pivotal study- 43USSA1705</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sculptra Aesthetic 8 ml and Lidocaine</intervention_name>
    <description>Treatment of nasolabial folds</description>
    <arm_group_label>Investigational Arm in pivotal study- 43USSA1705</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Randomized to Sculptra Aesthetic 8ml reconstitution and successfully completed study
             43USSA1705

        Exclusion Criteria:

          -  Medical condition that in the opinion of the Investigator would make the subject
             unsuitable for inclusion

          -  Other condition preventing the subject from entering the study in the Investigator's
             opinion

          -  Participation in any interventional clinical study throughout the duration of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Study Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Study Site</name>
      <address>
        <city>Solana Beach</city>
        <state>California</state>
        <zip>92075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Study Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Study Site</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <zip>77388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

